Marijuana is the most commonly abused illicit drug in the US. In recent years, interest has increased in using marijuana and its psychoactive components, the cannabinoids, for symptom relief in specific chronic illnesses. Despite its frequent illicit use,and its potential therapeutic benefits, we are just beginning to understand how cannabinoids produce their actions. The psychoactive effects of marijuana are primarily due to the activation by cannabinoids of a G protein-coupled receptor (CPCR), the CB1 cannabinoid receptor. The immunomodulatory effects of cannabinoids are likely mediated by another GPCR, the CB2 cannabinoid receptor. Despite their importance in determining the effects of cannabinoids, the molecular events associated with activation and regulation of both cannabinoid receptors are incompletely understood. This component of the program project draws on the resources and results of Core 2 and Project 1, combining chemistry, molecular biology and cell biology to understand cannabinoid receptor activation and desensitization in order to provide the insight necessaryto develop therapeutically useful cannabinoid drugs. This proposal focuses on determining how diverse ligands differentially stimulate cannabinoid receptor activation and desensitization and on the role of the cannabinoid receptor oligomerization in this cycle. These studies will be accomplished by completing the following specific aims: 1. To identify cannabimimetic ligands that signal efficiently, yet show little desensitization. 2. To determine the role of the receptor dimerization in CB1

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA009158-14
Application #
8261965
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
2014-04-30
Budget Start
2011-05-01
Budget End
2013-04-30
Support Year
14
Fiscal Year
2011
Total Cost
$170,640
Indirect Cost
Name
Northeastern University
Department
Type
DUNS #
001423631
City
Boston
State
MA
Country
United States
Zip Code
02115
Lin, Xiaoyan; Dhopeshwarkar, Amey S; Huibregtse, Megan et al. (2018) Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence. Mol Pharmacol 93:49-62
Slivicki, Richard A; Saberi, Shahin A; Iyer, Vishakh et al. (2018) Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. J Pharmacol Exp Ther 367:551-563
Straiker, Alex; Dvorakova, Michaela; Zimmowitch, Anaelle et al. (2018) Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons. Mol Pharmacol 94:743-748
Mallipeddi, Srikrishnan; Zvonok, Nikolai; Makriyannis, Alexandros (2018) Expression, Purification and Characterization of the Human Cannabinoid 1 Receptor. Sci Rep 8:2935
Slivicki, Richard A; Xu, Zhili; Kulkarni, Pushkar M et al. (2018) Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Biol Psychiatry 84:722-733
Li, Ai-Ling; Carey, Lawrence M; Mackie, Ken et al. (2017) Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther 362:296-305
Finlay, David B; Cawston, Erin E; Grimsey, Natasha L et al. (2017) G?s signalling of the CB1 receptor and the influence of receptor number. Br J Pharmacol 174:2545-2562
Ruehle, Sabine; Wager-Miller, James; Straiker, Alex et al. (2017) Discovery and characterization of two novel CB1 receptor splice variants with modified N-termini in mouse. J Neurochem 142:521-533
Hua, Tian; Vemuri, Kiran; Nikas, Spyros P et al. (2017) Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature 547:468-471
Dhopeshwarkar, Amey; Murataeva, Natalia; Makriyannis, Alex et al. (2017) Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists. J Pharmacol Exp Ther 360:300-311

Showing the most recent 10 out of 196 publications